Fosun Pharma (02196.HK) announced a proposal to privatize Henlius (02696.HK) through absorption and merger, with a cash cancellation price of HKD 24.6 per listed H share, representing a premium of 30.57% to the suspension price before for Henlius. The transaction involves approximately HKD 3.225 billion. Upon completion of the transaction, Henlius will apply for a voluntary delisting of its H shares from the Hong Kong Stock Exchange.
Trading of Henlius shares has resumed on Tuesday (25th).